Have we put "All our spike proteins in one basket"?
Loading player...
Exactly one weeks since the 1 million doses of the Oxford AstraZenica vaccine landed from the serum institute landed in the country, and we have had to change strategy…
In a worrying development, South Africa’s vaccine rollout was dealt a blow over the weekend after new evidence emerged that AstraZeneca’s vaccine does not protect people against mild to moderate disease caused by the new variant detected in SA late last year.
Michael Avery talks to Biovac CEO, Dr Morena Makhoana; Stavros Nicolaou head of the health working group for B4SA; & Patrick Tippoo, Director at the African Vaccine Manufacturing Initiative; about these developments and how they impact the vaccine rollout strategy broadly.
In a worrying development, South Africa’s vaccine rollout was dealt a blow over the weekend after new evidence emerged that AstraZeneca’s vaccine does not protect people against mild to moderate disease caused by the new variant detected in SA late last year.
Michael Avery talks to Biovac CEO, Dr Morena Makhoana; Stavros Nicolaou head of the health working group for B4SA; & Patrick Tippoo, Director at the African Vaccine Manufacturing Initiative; about these developments and how they impact the vaccine rollout strategy broadly.